Skip to main content
. 2023 Jan 4;41(8):1590–1599. doi: 10.1200/JCO.22.00940

FIG 2.

FIG 2.

Kaplan-Meier estimates of (A) OS and (B) PFS2 in the ITT population, which included all patients who underwent random assignment. D-Rd, daratumumab, lenalidomide, and dexamethasone; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; PFS2, progression-free survival on the subsequent line of therapy; Rd, lenalidomide and dexamethasone.